Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cogent Biosciences (COGT) Current Assets (2017 - 2026)

Cogent Biosciences' Current Assets history spans 10 years, with the latest figure at $877.8 million for Q1 2026.

  • Quarterly Current Assets rose 247.12% to $877.8 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $877.8 million through Mar 2026, up 247.12% year-over-year, with the annual reading at $910.4 million for FY2025, 207.06% up from the prior year.
  • Current Assets came in at $877.8 million for Q1 2026, down from $910.4 million in the prior quarter.
  • In the past five years, Current Assets ranged from a high of $910.4 million in Q4 2025 to a low of $194.7 million in Q1 2022.
  • The 5-year median for Current Assets is $296.5 million (2024), against an average of $372.8 million.
  • Year-over-year, Current Assets tumbled 42.77% in 2025 and then surged 247.12% in 2026.
  • Cogent Biosciences' Current Assets stood at $265.0 million in 2022, then increased by 2.19% to $270.8 million in 2023, then increased by 9.49% to $296.5 million in 2024, then soared by 207.06% to $910.4 million in 2025, then fell by 3.58% to $877.8 million in 2026.
  • Per Business Quant, the three most recent readings for COGT's Current Assets are $877.8 million (Q1 2026), $910.4 million (Q4 2025), and $397.2 million (Q3 2025).